Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Withdrawn 1Unknown 1Not yet recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 131Neoplasms, Plasma Cell 21Recurrence 20Lymphoma 14Lymphoma, Non-Hodgkin 13Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia, Myeloid, Acute 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myeloproliferative Disorders 11Lymphoma, Mantle-Cell 11Lymphoma, Follicular 11Lymphoma, B-Cell, Marginal Zone 11Leukemia 11Neoplasms 10Lymphoma, Large-Cell, Immunoblastic 10Lymphoma, Large B-Cell, Diffuse 10Hodgkin Disease 10Primary Myelofibrosis 9Myelodysplastic Syndromes 9Leukemia, Myelomonocytic, Chronic 9Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 9Congenital Abnormalities 9Waldenstrom Macroglobulinemia 8Sezary Syndrome 8Pdgfra-Associated Chronic Eosinophilic Leukemia 8Mycosis Fungoides 8Lymphoma, T-Cell, Cutaneous 8Leukemia, Neutrophilic, Chronic 8Leukemia, Myeloid, Accelerated Phase 8

Interventions

siltuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Cytokine Release Syndrome × Plasma cell × Clear all
NCT06352866 2025-03-03

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Case Comprehensive Cancer Center

Phase 2 Withdrawn
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡